Drug Approval | July 13, 2024
Lupin receives EIR from USFDA for its Dabhasa facility
The facility is a part of Lupin Manufacturing Solutions
The facility is a part of Lupin Manufacturing Solutions
The Unit has been issued GMP Certification from ANVISA-Brazil
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
This product will be manufactured at Lupin’s Pithampur facility in India
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Subscribe To Our Newsletter & Stay Updated
